Cardio Diagnostics Holdings, Inc. (CDIO): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$5.91M

Year ended 2025-12-31

-$5.82M

Trailing 12 months to 2026-06-30

2023-12-31 Free Cash Flow (USD) 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$5.91M	n/m	2026-03-13, From 2025-01-01
2024-12-31	-$5.21M	n/m	2026-03-13, From 2024-01-01
2023-12-31	-$6.25M	n/a	2025-03-20, From 2023-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Cardio Diagnostics Holdings, Inc. (CDIO)	2025-12-31	-$5.91M	n/m
Celldex Therapeutics, Inc. (CLDX)	2025-12-31	-$213.66M	n/m
Volitionrx Ltd (VNRX)	2025-12-31	-$19.77M	n/m
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	-$25.37M	n/m
Aspira Women's Health Inc. (AWHL)	2025-12-31	-$7.04M	n/m
Immucell Corp (ICCC)	2025-12-31	$1.22M	n/m
Alpha Teknova, Inc. (TKNO)	2025-12-31	-$9.79M	n/m
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	-$395.87M	n/m
Neogen Corp (NEOG)	2026-05-31	$31.90M	n/m

Compare CDIO, CLDX, VNRX, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗